Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

News | Heart Failure

Dapagliflozin Reduces Heart Failure Worsening and Death in DAPA-HF Sub-analysis

March 28, 2020 — New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of Adverse ...

March 28, 2020

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. #ACC20 #ACC2020

News | Antiplatelet and Anticoagulation Therapies

Antiplatelet Genetic Testing Missed Goal to Cut Cardiovascular Events in Half

March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to ...

March 28, 2020

The VOYAGER PAD trial showed patients with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15 percent reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone. #ACC20

News | Peripheral Artery Disease (PAD)

Rivaroxaban Reduces Risks in Peripheral Artery Disease Post-Intervention

March 28, 2020 — People with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with ...

March 28, 2020

Hydroxychloroquine causes prolonged QT intervals and cardiac arrhythmias, so this needs to be considered in patients being treated with this drug for COVID-19. #COVID19 #SARScov2 #coronavirus

Feature | Coronavirus (COVID-19) | Marianne Pop, Pharm.D, BCPS

COVID-19 Hydroxychloroquine Treatment Brings Prolonged QT Arrhythmia Issues

It has been more than three months since the word coronavirus was uttered on everyone’s lips and all over the social ...

March 24, 2020

The U.S. Food and Drug Administration (FDA) approved Esperion's bempedoic acid (Nexletor) tablet, an oral, once-daily, non-statin low-density lipoprotein cholesterol (LDL-C) lowering medicine. The drug is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C.

Feature | Pharmaceuticals

FDA Clears Bempedoic Acid Non-statin LDL-cholesterol Lowering Drug

February 24, 2020 — The U.S. Food and Drug Administration (FDA) approved Esperion's bempedoic acid (Nexletor) tablet, an ...

February 24, 2020

Videos | Antiplatelet and Anticoagulation Therapies

VIDEO: Optimizing Platelet Inhibition in the Cath Lab at Tufts Medical Center

Carey Kimmelstiel, M.D., FACP, FACC, director, interventional cardiology, director, cardiac catheterization lab, Tufts ...

February 18, 2020

The U.S. Food and Drug Administration (FDA) has approved a the CATALYST trial designed to assess Abbott's Amplatzer Amulet left atrial appendage (LAA) occluder for people with atrial fibrillation (AF or AFib).

News | Left Atrial Appendage (LAA) Occluders

Amplatzer Amulet LAA Occluder Will be Compared to Anticoagulants in CATALYST Trial

February 3, 2020 — The U.S. Food and Drug Administration (FDA) has approved a the CATALYST trial designed to assess ...

February 03, 2020

Indications expanded for Ozempic and Rybelsus to reduce cardiovascular risk in adults with type 2 diabetes and known heart disease

News | Pharmaceuticals

FDA Clears Semaglutide For Cardiac Risk Reduction in Diabetic Patients

January 29, 2020 - The U.S. Food and Drug Administration (FDA) has approved a new indication for Novo Nordisk's Ozempic ...

January 29, 2020

This image shows the cardiac muscle fibers of a fruit fly under magnification. Iowa State University researchers have found a way to restore the strength and regularity of cardiac muscles in aging fruit flies. Photo by Hua Bai, Iowa State University.

News | Pharmaceuticals

Fruit Fly Hearts Show How to Keep Human Cardiac Muscle Young

January 9, 2020 – Researchers may have discovered a way to turn back the clock on aging heart muscles in fruit flies, a ...

January 09, 2020

$The U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) from AstraZeneca and granted priority review for dapagliflozin (Farxiga) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure (HF) in adults with heart failure with reduced ejection fraction (HFrEF) with and without type 2 diabetes (T2D).$

News

Dapagliflozin Granted FDA Priority Review for Heart Failure With Reduced Ejection Fraction

January 7, 2020 — The U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) ...

January 07, 2020

News | Pharmaceuticals

Study Finds Drug Therapy for High Triglycerides to Have a Sustained Effect Using Low Dosages

December 30, 2019 — A drug therapy targeting the production of a protein produced by the liver has led to sustained and ...

December 30, 2019

The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

Feature | Antiplatelet and Anticoagulation Therapies

FDA Clears First Generics for Eliquis

December 27, 2019 — The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of ...

December 27, 2019

Vascepa pill contains a concentrated form of fish oil, icosapent ethyl, indication for prevention. The U.S. Food and Drug Administration (FDA) Dec. 13, 2019, approved the use of Vascepa (icosapent ethyl) capsules as an adjunctive therapy to reduce the risk of cardiovascular events in adults with elevated triglyceride levels.

Feature | Pharmaceuticals | Dave Fornell, Editor

FDA Expands Vascepa to Reduce Cardiovascular Events in Elevated Triglyceride Patients

December 16, 2019 — The U.S. Food and Drug Administration (FDA), on Dec. 13, approved the use of Vascepa (icosapent ...

December 16, 2019

News | Antiplatelet and Anticoagulation Therapies

Low-dose Aspirin May Not Help African Americans Prevent Heart Disease

December 12, 2019 — Low-dose aspirin was not associated with a reduced risk of a fatal heart attack among African ...

December 12, 2019

News | Cardiovascular Clinical Studies

Virtual Study to Track Statin-Related Adverse Events Being Undertaken by University of Connecticut and Hartford Healthcare

November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have ...

November 26, 2019